On August 13, 2026, ICON Investments Six Designated Activity Company, a wholly-owned subsidiary of ICON plc, issued $2.15 billion in senior unsecured notes consisting of $500 million of 5.064% Notes due 2029, $1.0 billion of 5.421% Notes due 2031, and $650 million of 5.995% Notes due 2036. ICON plc provided a senior unsecured guarantee for the issuance. The net proceeds were used to repay all outstanding term loans under the senior secured term loan facility on August 13, redeem the outstanding 5.809% Senior Secured Notes due 2027 on August 14, and repay borrowings under the bridge facility credit agreement on August 17. Consequently, collateral securing the revolving credit facility and subsidiary guarantees under existing notes were released. ICON plc operates in the clinical research organization industry.

ICON plc announced the pricing of a $2.15 billion private offering of senior unsecured notes, consisting of $500 million of 5.064% Notes due 2029, $1.0 billion of 5.421% Notes due 2031, and $650 million of 5.995% Notes due 2036. The offering is expected to close on August 13, 2026, subject to customary conditions. Net proceeds will repay the bridge facility credit agreement, outstanding senior secured term loans, and fully redeem the 5.809% Senior Secured Notes due 2027. Repayment of these obligations will release collateral securing the revolving credit facility and existing notes, while releasing subsidiary guarantees under those instruments. ICON plc is a world-leading clinical research organization that provides integrated consulting, clinical development, commercialization, and post-marketing solutions to pharmaceutical, biotechnology, medical device, government, and public health organizations.

ICON plc completed the disposal of Symphony Health Solutions Corporation to HealthVerity on May 8, 2026, recording a $32.9 million loss and retaining a minority equity interest in HealthVerity. The company also executed a bridge secured credit facility, drawing down $500.0 million on July 15, 2026, to fully repay its maturing 2.875% Senior Secured Notes due July 2026. For the six months ended June 30, 2026, revenue increased to $4.1 billion from $4.05 billion in the prior year period, while net income declined significantly to $177.3 million from $364.3 million due to restructuring charges and the disposal loss. ICON plc operates as a global contract research organization providing outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients.